Regeneron agreed to acquire 23andMe for $256 million. At its peak, 23andMe's market value swelled to $5.8 billion. Recently, ...

Regeneron bids for 23andMe at a discounted price of $256 million. The testing firm was once valued at $3.5 billion.

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

The sale brings attention back to privacy concerns as Regeneron now controls genetic data from millions of 23andMe customers.

Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March following a series of setbacks.

A view of 23andMe headquarters in Sunnyvale, Calif., March 25, 2025. Tayfun Coskun/Anadolu via Getty Images Regeneron on Monday vowed to maintain the data privacy protocol employed by 23andMe.

Regeneron is set to acquire 23andMe’s consumer genetics and research assets for $256 million. Here’s what the deal means for ...

Regeneron Pharmaceuticals has acquired 23andMe – and the genetic data for 15 million customers along with it. Credit: Tiffany Hagler-Geard/Bloomberg via Getty Images 23andMe had all the signs of ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million ...

PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data ...